# PreciseDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precisedx

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.precisedx.ai/
- Total disclosed funding: $43M
- Latest round: Series A (May 28, 2025)
- Investors on record: 10

## About

Based in New York, US, and founded in 2020 by CTO Jack Zeineh, CSO Gerardo Fernandez, CMO Michael Donovan, and Chairman of the Advisory Board Carlos Cordon-Cardo. PreciseDx operates as a cancer risk stratification company designed to leverage an AI-powered Morphology Feature Array.Its CEO is Wayne Brinster.In June 2025, PreciseDx raised USD 11 million in venture funding co-led by new investor Philips Health Technology Ventures and returning investors Eventide Asset Management and Merck Global Health Innovation Fund, with participation from other returning investors LabCorp Ventures, Quest Diagnostics, and GenHenn Capital. Other unspecified investors also participated in the round. PreciseDx offers Morphology Feature ArrayTM, a personalized medicine based on artificial intelligence that provides patient-specific risk information based on morphology feature analysis. It combines critical tissue-derived information with clinical data. The company's platform enables individualized treatment plans and improved patient outcomes. The company's products include breast tests and prostate tests. The company plans to utilize the June 2025 funding to focus on enhancing its clinical data collection, expanding its commercial efforts, and preparing for the launch of its flagship product, PreciseBreast, in 2026.

## Funding rounds

- Series A, May 28, 2025, $11M — Merck Global Health Innovation Fund, Eventide Asset Management, LabCorp Ventures, Quest Diagnostics, Philips Health Technology Ventures, GenHenn Capital
- Series B, Feb 20, 2024, $21M — Eventide Asset Management, LabCorp Ventures, Quest Diagnostics, GenHenn Capital
- Series A, Jan 11, 2022, $11M — Mount Sinai Health System, Agilent Technologies, IBM Ventures, Merck Global Health Innovation Fund, Hobart Group

## Investors

- Mount Sinai Health System — Series A
- Agilent Technologies — Series A
- IBM Ventures (https://capitalatlas.ai/funds/ibm-ventures) — Series A
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A
- Hobart Group (https://capitalatlas.ai/funds/hobart-group) — Series A
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B, Series A
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Series B, Series A
- Quest Diagnostics — Series B, Series A
- GenHenn Capital — Series B, Series A
- Philips Health Technology Ventures (https://capitalatlas.ai/funds/philips-health-technology-ventures) — Series A